We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Geron’s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

News   Jun 13, 2007

 
Geron’s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
 
 
Advertisement
 

RELATED ARTICLES

Experts Respond to Reported Death of COVID-19 Vaccine Trial Participant

News

News has emerged from Brazil that a participant of the Phase III clinical trial investigating the COVID-19 vaccine, ChAdOX1, has died.

READ MORE

Gut Bacteria May Be Responsible for Adverse Effect of Parkinson's Drug

News

Bacteria in the small intestine can deaminate levodopa, the main drug that is used to treat Parkinson's disease.

READ MORE

Researchers Use Lab-Grown Tissue Grafts for Personalized Joint Replacement

News

A team led by Columbia Engineering has bioengineered anatomically precise living grafts for personalized replacement of a jaw joint, using the recipient's fat-derived cells, and demonstrated effectiveness in a clinically sized swine model.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE